

Listing of Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A composition ~~in dosage form suitable for non-parenteral administration~~ comprising at least one ~~antisense~~ oligonucleotide in an emulsion and a bile salt, wherein said bile salt is selected from the group consisting of cholic acid, dehydrocholic acid, deoxycholic acid, glucolic acid, glycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, sodium tauro-24,25-dihydrofusidate, sodium glycodihydrofusidate, polyoxyethylene-9-lauryl ether and a pharmaceutically acceptable salt thereof ~~wherein said antisense oligonucleotide modulates expression of a cellular adhesion protein, modulates a rate of cellular proliferation, or has biological activity against eukaryotic pathogens or retroviruses.~~

2-3. (Cancelled).

4. (Previously presented) The composition of claim 1 wherein said oligonucleotide is a ribozyme or a peptide nucleic acid.

5. (Original) The composition of claim 1 wherein said emulsion is selected from the group consisting of an oil-in-water emulsion, a water-in-oil emulsion, an oil-in-water-in-oil emulsion, and a water-in-oil-in water emulsion.

6. (Original) The composition of claim 1 wherein said emulsion is a microemulsion.

7. (Previously presented) The composition of claim 6 wherein said microemulsion is selected from the group consisting of an oil-in-water microemulsion, a water-in-oil microemulsion, an oil-in-water-in-oil microemulsion, and a water-in-oil-in water microemulsion.

8-11. (Cancelled).

12. (Cancelled)

13. (Previously presented) The composition of claim 1 further comprising at least one fatty acid.

14-18. (Cancelled).

19. (Original) The composition of claim 1 further comprising at least one carrier compound.

20. (Previously presented) The composition of claim 19 wherein said carrier compound is selected from the group consisting of polyinosinic acid, dextran sulfate, polycytidic acid, and 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid.

21-79. (Cancelled).

80. (Currently amended) The composition according to claim 1, wherein said oligonucleotide comprises is SEQ ID NO:1.

81-83. (Cancelled).

84. (previously presented) The composition of claim 1 wherein said emulsion is an oil-in-water-in-oil emulsion or a water-in-oil-in-water emulsion.

85. (previously presented) The composition according to claim 1, wherein said oligonucleotide is selected from the group consisting of SEQ ID NOS: 2, 48, 49, 50, 16, 19, 51, 52, 53, and 54.

86-90. (Cancelled).

91. (Currently amended) The composition of claim 1 ~~87~~ in dosage form suitable for non-parenteral administration.

92-94. (Cancelled).

95. (Previously presented) The composition of claim 1 in oral dosage form.

96. (Cancelled).